Skip to content

Study · Randomized controlled trial · 2024

9 results

Evaluation of supplementary carnosine accumulation and distribution: an initial analysis of participants in the Nucleophilic Defense Against PM Toxicity (NEAT) clinical trial.

Baba SP, Amraotkar AR, Hoetker D, Gao H, Gomes D, Zhao J, Wempe MF, Rice PJ, DeFilippis AP, Rai SN, Pope CA 3rd, Bhatnagar A, O'Toole TE

Amino acids31 Aug 2024Cited by 9 (Europe PMC)

PMID39215872 (opens in a new tab)PMCIDPMC11365863 (opens in a new tab)DOI10.1007/s00726-024-03414-5 (opens in a new tab)PepBankPUB-39215872
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In supplemented participants, carnosine approximately doubled red blood cell carnosine compared with placebo after 6 or 12 weeks.

    In plain wordsIn participants, carnosine approximately doubled red blood cell carnosine compared with placebo after 6 or 12 weeks.

    Peptide
    L-carnosine
    Outcome
    IncreaseRed blood cell carnosine
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    2 g/day · oral · 6 or 12 weeksAs given in this study (human).

    Measurements

    RBC carnosine increase
    ≈ 2 fold
    6 or 12 weeks

    Source sentences

    Summary
    We found that, when compared with placebo, supplementation with carnosine for 6 or 12 weeks led to an approximate twofold increase in RBC carnosine, while levels of urinary carnosine increased nearly sevenfold.
    2 context sentences
    Summary · context
    To do this, we randomized a cohort to receive daily supplements of either placebo or carnosine (2 g/day).
    Summary · context
    Blood and urine samples were collected twice over the subsequent 12 week supplementation period and we measured levels of red blood cell (RBC) carnosine, urinary carnosine, and urinary carnosine-propanol and carnosine-propanal conjugates by LC/MS-MS.
  2. 02HumanRandomized controlled trialPharmacokinetics

    In supplemented participants, urinary carnosine increased nearly sevenfold compared with placebo.

    In plain wordsIn participants, urinary carnosine rose nearly sevenfold with supplementation compared with placebo.

    Peptide
    L-carnosine
    Outcome
    IncreaseUrinary carnosine
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    2 g/day · oral · 6 or 12 weeksAs given in this study (human).

    Measurements

    Urinary carnosine increase
    ≈ 7 fold

    Source sentences

    Summary
    We found that, when compared with placebo, supplementation with carnosine for 6 or 12 weeks led to an approximate twofold increase in RBC carnosine, while levels of urinary carnosine increased nearly sevenfold.
    2 context sentences
    Summary · context
    To do this, we randomized a cohort to receive daily supplements of either placebo or carnosine (2 g/day).
    Summary · context
    Blood and urine samples were collected twice over the subsequent 12 week supplementation period and we measured levels of red blood cell (RBC) carnosine, urinary carnosine, and urinary carnosine-propanol and carnosine-propanal conjugates by LC/MS-MS.
  3. 03HumanRandomized controlled trialPharmacokinetics

    In supplemented participants, carnosine did not change urinary carnosine propanol levels.

    In plain wordsIn participants, carnosine did not change urinary carnosine propanol compared with placebo.

    Peptide
    L-carnosine
    Outcome
    No significant changeUrinary carnosine propanol
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    2 g/day · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Although there were no changes in the urinary levels of carnosine propanol, carnosine propanal increased nearly twofold.
    2 context sentences
    Summary · context
    To do this, we randomized a cohort to receive daily supplements of either placebo or carnosine (2 g/day).
    Summary · context
    Blood and urine samples were collected twice over the subsequent 12 week supplementation period and we measured levels of red blood cell (RBC) carnosine, urinary carnosine, and urinary carnosine-propanol and carnosine-propanal conjugates by LC/MS-MS.
  4. 04HumanRandomized controlled trialPharmacokinetics

    In supplemented participants, urinary carnosine propanal increased nearly twofold.

    In plain wordsIn participants, carnosine increased urinary carnosine propanal nearly twofold compared with placebo.

    Peptide
    L-carnosine
    Outcome
    IncreaseUrinary carnosine propanal
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    2 g/day · oral · 12 weeksAs given in this study (human).

    Measurements

    Urinary carnosine propanal increase
    ≈ 2 fold

    Source sentences

    Summary
    Although there were no changes in the urinary levels of carnosine propanol, carnosine propanal increased nearly twofold.
    2 context sentences
    Summary · context
    To do this, we randomized a cohort to receive daily supplements of either placebo or carnosine (2 g/day).
    Summary · context
    Blood and urine samples were collected twice over the subsequent 12 week supplementation period and we measured levels of red blood cell (RBC) carnosine, urinary carnosine, and urinary carnosine-propanol and carnosine-propanal conjugates by LC/MS-MS.
  5. 05HumanRandomized controlled trialSafety outcome

    In participants receiving carnosine or placebo, neither arm reported adverse reactions.

    In plain wordsIn participants, neither the carnosine arm nor the placebo arm reported adverse reactions.

    Peptide
    L-carnosine
    Outcome
    Not applicableAdverse reactions
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    2 g/day · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    No adverse reactions were reported by those in the carnosine or placebo arms, nor did carnosine supplementation have any effect on kidney, liver, and cardiac function or blood electrolytes.
    2 context sentences
    Summary · context
    To do this, we randomized a cohort to receive daily supplements of either placebo or carnosine (2 g/day).
    Summary · context
    Blood and urine samples were collected twice over the subsequent 12 week supplementation period and we measured levels of red blood cell (RBC) carnosine, urinary carnosine, and urinary carnosine-propanol and carnosine-propanal conjugates by LC/MS-MS.
  6. 06HumanRandomized controlled trialSafety outcome

    In supplemented participants, carnosine had no effect on kidney function.

    In plain wordsIn participants, carnosine did not change kidney function compared with placebo.

    Peptide
    L-carnosine
    Outcome
    No significant changeKidney function
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    2 g/day · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    No adverse reactions were reported by those in the carnosine or placebo arms, nor did carnosine supplementation have any effect on kidney, liver, and cardiac function or blood electrolytes.
    2 context sentences
    Summary · context
    To do this, we randomized a cohort to receive daily supplements of either placebo or carnosine (2 g/day).
    Summary · context
    Blood and urine samples were collected twice over the subsequent 12 week supplementation period and we measured levels of red blood cell (RBC) carnosine, urinary carnosine, and urinary carnosine-propanol and carnosine-propanal conjugates by LC/MS-MS.
  7. 07HumanRandomized controlled trialSafety outcome

    In supplemented participants, carnosine had no effect on liver function.

    In plain wordsIn participants, carnosine did not change liver function compared with placebo.

    Peptide
    L-carnosine
    Outcome
    No significant changeLiver function
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    2 g/day · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    No adverse reactions were reported by those in the carnosine or placebo arms, nor did carnosine supplementation have any effect on kidney, liver, and cardiac function or blood electrolytes.
    2 context sentences
    Summary · context
    To do this, we randomized a cohort to receive daily supplements of either placebo or carnosine (2 g/day).
    Summary · context
    Blood and urine samples were collected twice over the subsequent 12 week supplementation period and we measured levels of red blood cell (RBC) carnosine, urinary carnosine, and urinary carnosine-propanol and carnosine-propanal conjugates by LC/MS-MS.
  8. 08HumanRandomized controlled trialSafety outcome

    In supplemented participants, carnosine had no effect on cardiac function.

    In plain wordsIn participants, carnosine did not change heart function compared with placebo.

    Peptide
    L-carnosine
    Outcome
    No significant changeCardiac function
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    2 g/day · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    No adverse reactions were reported by those in the carnosine or placebo arms, nor did carnosine supplementation have any effect on kidney, liver, and cardiac function or blood electrolytes.
    2 context sentences
    Summary · context
    To do this, we randomized a cohort to receive daily supplements of either placebo or carnosine (2 g/day).
    Summary · context
    Blood and urine samples were collected twice over the subsequent 12 week supplementation period and we measured levels of red blood cell (RBC) carnosine, urinary carnosine, and urinary carnosine-propanol and carnosine-propanal conjugates by LC/MS-MS.
  9. 09HumanRandomized controlled trialSafety outcome

    In supplemented participants, carnosine had no effect on blood electrolytes.

    In plain wordsIn participants, carnosine did not change blood electrolytes compared with placebo.

    Peptide
    L-carnosine
    Outcome
    No significant changeBlood electrolytes
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    2 g/day · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    No adverse reactions were reported by those in the carnosine or placebo arms, nor did carnosine supplementation have any effect on kidney, liver, and cardiac function or blood electrolytes.
    2 context sentences
    Summary · context
    To do this, we randomized a cohort to receive daily supplements of either placebo or carnosine (2 g/day).
    Summary · context
    Blood and urine samples were collected twice over the subsequent 12 week supplementation period and we measured levels of red blood cell (RBC) carnosine, urinary carnosine, and urinary carnosine-propanol and carnosine-propanal conjugates by LC/MS-MS.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableResults postedNCT03314987

Nucleophilic Defense Against PM Toxicity (NEAT Trial)

University of Louisvillen = 2991 Apr 2018 to 1 Nov 2022

Air Pollution Toxicity

Trial pageClinicalTrials.govUpdated 6 Jan 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.